Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. 
Cis-dichlorodiammineplatinum(II) was used in the treatment of 34 patients with advanced adenocarcinoma of the ovary who were resistant to conventional chemotherapy.  Two dose schedules were explored: a high-dose schedule with 30 mg/m2 given daily on 3 successive days every 4 weeks and a low-dose schedule with 30 mg/m2 given once every 2-3 weeks.  Nine patients (26.5%) showed a therapeutic response with a median duration of 6 months (range, 3-15 months).  The main toxic effects included myelosuppression, renal function impairment, and nausea and vomiting.  The high-dose schedule proved to be more toxic without any therapeutic advantage.